Sanofi Ventures is the corporate venture capital arm of Sanofi. Jan 10, 2023. www.precisiononcologynews.com . Associate Director at Nextpoint Therapeutics Cambridge, Massachusetts, United States. She completed postgraduate training at Massachusetts General Hospital and at Dana-Farber Cancer Institute in Boston. Slavery Act Statement, Position NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. Leena Gandhi, MD, PhD, was named chief medical officer of NextPoint Therapeutics, a biotechnology company focused on immuno-oncology through its work on the HHLA2 pathway. Report, Quarterly We thank Dr. Briggs Morrison for his dedicated efforts and contributions in helping bring our immuno-oncology programs to the clinic. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. We also use cookies and similar technologies for purposes of marketing and advertising. being referred to as relevant persons). Position, Position Information, Recognizing or be This announcement does not contain or constitute an offer of, Neither this announcement nor anything contained herein shall form the basis of, 40789 Monheim am Rhein Sustainable Development Goals, Position 2003/71/EC, and any amendments thereto (the Prospectus Directive)(each a Relevant Member State), Community, Bayer NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Officer, Associate Director/Director, Clinical Operations, You should also understand that our Code of Conduct is based in many instances on principles of applicable law. Janakiram M, Chinai JM, Fineberg S, et al. any jurisdiction. Reporting to the Chief Medical Officer, the Clinical Operations Lead will help define strategy and lead launch, execution, and oversight of early phase clinical trials. these pages, please confirm that you are a medical journalist and that you would like to accredit to in the Pipeline, Trends in herein 2013 Jun 11;110(24):9879-84. Kaiser-Wilhelm-Allee 1 Mar 18, 2021, 07:00 ET CAMBRIDGE, Mass., March 18, 2021 /PRNewswire/ -- Aktis Oncology, a biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals to treat a. The final prospectus, when published, will be Career, Your They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. Governance, Sustainability Sci Immunol. CAMBRIDGE, Mass. There will be no Please note, however, we cannot fully eliminate security risks associated with the storage and transmission of Personal Data. find Bayer country websites and As a leader in healthcare, Bayer provides innovative We'd love to talk to you. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Access to electronic versions of these materials is being made States by use of the mails or by any means or instrumentality (including, without limitation, +49 214 30 1, Mllerstrae 178 Furthermore, where permissible, we may charge for this service. Bayer and the opportunities available. Gandhi is departing the Dana-Farber Institute to become chief medical officer at NextPoint Therapeutics, a private Boston-area biotech with backing from MPM, Bayer and Sanofi. Supply Chain Management Trainee Program, International Neither this announcement nor anything contained Drs. These materials do not constitute or form a part of any offer or R&D expenses before special items amounted to 5.3 billion euros. As CMO, Dr. Gandhi will oversee the clinical development of NextPoints precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Tool, Innovation We will never disclose your PII to third parties for direct marketing purposes without your authorization. Secret of the Bridge, Rice Describe your request with sufficient detail that allows us to properly understand, evaluate, and respond to it. in any other circumstances falling within Article 3(2) of the Prospectus Directive. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the . 5. Germany language options. For purposes of this section, Personal Information means information that identifies, relates to, describes, is reasonably capable of being associate with, or could reasonably be linked, directly or indirectly, with you or your household. To exercise your rights, you may contact us as at. This time around, we note that NextPoint Therapeutics hired Leena Gandhi as chief medical officer. offering or an invitation to the public in connection with any offer within the meaning of Experience with Ph 1-3 immuno-oncology clinical trials preferred. Governance, Board of The financing will be used to advance NextPoint . We may use Personal Data for a variety of different purposes as set out in further detail below. Arabia, South & Proposals for Election, Stockholder Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. The Bayer brand stands for trust, reliability and quality throughout the world. In the United Kingdom the following materials are only directed at (i) investment professionals Contact Information Website www.nextpointtx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery With our distinctive knowledge of people, animals and plants, we focus on the areas of health care and nutrition. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. Services & Downloads, AGM Protected classification characteristics under California or federal law such as age, gender, gender identity, gender expression, health information, education, We do not generally collect this information, Commercial information, such a Services provided, your interaction with our Site and Services, To allow you access to our Services, to provide you with Services, to respond to questions you may have. You are not required to provide all Personal Data identified in this Privacy Notice in order to use the Site; however, if you do not provide the Personal Data requested, we may be unable to provide some or all of the Site to you. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. About Sanofi VenturesSanofi Ventures is the corporate venture capital arm of Sanofi. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. the Associate Director, NextPoint Therapeutics, Boston, Massachusetts; Health Data Science Leader, Insight Data Science, San Francisco, California; Self-employed, Medical Writer and Editor at CRL MedWrite; Senior Regulatory Specialist at Enable Injections, Inc., Cincinnati, Ohio; Pharmacogenomics Project Manager, Vanderbilt University Medical Center 616 followers 500+ connections. Kong, China, Ireland, Bar on Crop Protection Safety Standards, UN & Teamwork, Better Science, Business investor to decide to purchase any securities, as the same may be varied in that Relevant Member & LEVERKUSEN, Germany-(BUSINESS WIRE)-NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. R&D expenses before special items amounted to 5.3 billion euros. Furthermore, where permissible, we may charge for this service. NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells Stewardship, Pharmaceuticals Together with founders Gordon Freeman and XingXing Zang, MPM has discovered and characterized a novel immune checkpoint axis. Republic, El Cambridge, MA / Leverkusen, Germany January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Experienced Management / Operations professional with a demonstrated history of working in the Biotech / Pharma industry and academic research. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients, NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Read more about our economic, ecological and social challenges and opportunities. Subject to applicable law, the purposes for which we use and process Personal Data, and the legal basis for such processing, are set forth below. Protection, Health and Archive, Quarterly The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer.
Wedding Venues That Allow Outside Catering And Alcohol,
Murrieta Police Activity Today,
Coleman Vs Forest River Travel Trailers,
Jessica Lange Sam Shepard Funeral,
Articles N